Asthma and Allergies
Drugs for Asthma and Allergies
Overview of medications used in the treatment of asthma and allergies:
Short Acting Beta Agonists
Inhaled Corticosteroids
Long Acting Beta Agonists
Leukotriene Modifiers
Systemic Corticosteroids
Methylxanthines
Antihistamines
Corticosteroid Nasal Sprays
Mast Cell Stabilizers
Ophthalmic agents (e.g., NSAID, Steroid, Antihistamine)
Asthma Control Objectives
Aiming to achieve the following outcomes in asthma management:
Prevent chronic and troublesome symptoms such as:
Coughing or breathlessness during the night, daytime, or after exertion.
Maintain (near) normal pulmonary function.
Maintain normal activity levels, including exercise and attending school or work.
Require infrequent use of inhaled short-acting β2-agonist for quick symptom relief (not including prevention of exercise-induced bronchospasm).
Meet patients’ and families’ expectations regarding asthma care.
Prevent recurrent exacerbations and minimize emergency department visits or hospitalizations.
Preserve lung function and prevent reduced lung growth in children.
Provide optimal pharmacotherapy with minimal or no adverse effects.
Source: Adapted from the National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program (NAEPP), 2007.
Overview of Asthma
Definition:
Chronic inflammatory disease of the airways characterized by:
Obstruction due to bronchoconstriction, edema, and excessive mucus production.
Symptoms include:
Wheezing
Coughing
Shortness of breath
Chest tightness
Exercise-Induced Bronchospasm (EIB)
Characteristics:
Symptoms may not be present at other times.
Onset occurs during exercise and lasts for 20 to 60 minutes afterward.
Peak bronchospasm typically occurs within the first 5 to 15 minutes of exercise.
Symptoms are similar to those of chronic asthma.
Pathology of Asthma
Normal airway vs. asthmatic airway differences:
Normal airway:
Relaxed smooth muscles, unobstructed airflow.
Asthmatic airway:
Wall inflammation and thickening.
During an asthma attack, airway tissues become constricted and inflamed.
Chemical Mediators in Asthma
Membrane Bound Arachidonic Acid involved in:
Breakdown by Phospholipase A2 into several mediators:
Prostaglandins
Thromboxanes
Leukotrienes
Prostacyclin
Other mediators include:
Histamine
Platelet-activating factor
Cytokines
Mixed activity of these mediators can:
Cause either bronchoconstriction or bronchodilation.
Asthma Triggers
Common triggers include:
Pet allergens
Dust mites
Fungal spores
Infections
Tobacco smoke
Pollen
Chemical exposure
Comorbid conditions (additional health problems).
Asthma Classification
Intermittent Asthma
Symptoms occur no more than:
2 days/week
Night awakenings: no more than 2 times/month.
Rescue inhaler use: no more than 2 times/week.
No interference with normal activity.
Normal lung function indicators.
Fewer than 2 exacerbations/year requiring oral corticosteroids.
Mild Persistent Asthma
Symptoms occur:
More than 2 days/week but not daily.
Night awakenings 3 to 4 times/month.
Rescue inhaler use more than 2 times/week (not daily, not more than once/day).
Minor activity limitations.
Abnormal lung function with 2 or more exacerbations/year needing oral corticosteroids.
Moderate Persistent Asthma
Symptoms are:
Daily occurrence.
Night awakenings more than once/week but not nightly.
Daily rescue inhaler use with some activity limitations.
Abnormal lung function indicators with 2 or more exacerbations/year requiring oral corticosteroids.
Severe Persistent Asthma
Symptoms persist:
Throughout the day.
Night awakenings are often daily.
Rescue inhaler use several times/day.
Significant activity limitations.
Abnormal lung function with 2 or more exacerbations/year requiring oral corticosteroids.
Asthma Management Steps
Step 1: Intermittent asthma
Preferred: Short-Acting Beta Agonist (SABA) as needed.
Step 2: Mild persistent asthma
Preferred: Low-dose Inhaled Corticosteroid (ICS).
Step 3: Moderate persistent asthma
Preferred: Medium-dose ICS + Long-Acting Beta Agonist (LABA).
Alternative: Low-dose ICS + either Leukotriene receptor antagonists (LTRA) or Theophylline.
Step 4: Severe persistent asthma
Preferred: High-dose ICS + LABA.
Consultation with asthma specialist is advised.
Step 5: Higher treatment intensity if needed.
Step 6: Adjust medication based on control and symptoms.
Each step includes patient education and monitoring environmental factors.
Inhalers and Spacers
Local delivery benefits include:
Better pharmacokinetic parameters.
Avoidance of gastrointestinal absorption, first-pass effect, and systemic distribution.
Importance of proper technique in effective therapy.
Peak Flow Meters
Purpose and Usage:
Allows patients to monitor peak expiratory flow (PEF).
Determine personal best PEF during a controlled asthma period.
Decreased PEF may indicate imminent asthma attacks.
Pre-established management plan for PEF decreases is necessary.
Quick-Relief Drugs
Function: Treat symptoms of acute asthma attacks and prevent imminent attacks.
Not used on a routine basis; available for all asthma patients.
Rapid onset inhaled β2-agonist is the primary medication.
Adrenergic Receptors
Types:
β1 receptors:
Heart effects: Increase heart rate, myocardial contractility, and conduction velocity as well as renin release from kidneys.
β2 receptors:
Bronchi: Bronchodilation.
Skeletal muscle: Stimulate contraction.
Liver: Glycogenolysis and gluconeogenesis.
Short-Acting β2-Agonists
Primary medications for acute attacks:
Onset of action within 5 minutes and duration between 2 to 6 hours.
Albuterol is the most frequently used.
Frequent use prior to exercise requires reevaluation of long-term therapy.
Anticholinergics
Mechanism: Inhibition of cholinergic receptors in the parasympathetic nervous system.
Induce bronchodilation but are less effective than β2-agonists.
Not commonly used for asthma, but can assist during acute attacks and are effective in COPD (e.g., Ipratropium).
Systemic Corticosteroids
Function: Anti-inflammatory activity.
Not routinely used, but can be combined with SABA in specific situations (e.g., Methylprednisolone, Prednisone, Dexamethasone).
Long-Term Therapy for Asthma
Purpose: Reducing the incidence of acute attacks via scheduled medication therapy.
Available options:
Inhaled corticosteroids
Long-acting β2-agonists
Mast cell stabilizers
Leukotriene modifiers
Methylxanthines
Inhaled Corticosteroids
Mainstay of long-term therapy:
Preferred for persistent asthma.
Decreases frequency/severity of attacks and improves nocturnal asthma control.
Can increase dose or add LABA for worsening asthma symptoms.
Common Inhaled Corticosteroids and Dosing Details
Drug Name / Dosage Form / Dosing Interval:
Fluticasone (Flovent): MDI, 2 times/day.
Budesonide (used in combination): DPI, 2 times/day.
Flunisolide (Aerobid): MDI, 2 times/day.
Inhaled Corticosteroids: Adverse Effects
Local Effects:
Hoarseness, cough, thrush; minimized by using spacer and rinsing mouth after use.
Systemic Effects:
Growth suppression in children, decreased bone mineralization, and risk of cataracts.
Long-Acting β-Agonists
Inhaled bronchodilators with extended-release oral tablets available:
Slower onset than short-acting agonists.
Not for rescue therapy.
Beneficial in reducing rescue inhaler use and nocturnal asthma symptoms.
Common Long-Acting β-Agonists & Dosing
Drug Name / Dosage Form / Dosing Interval:
Salmeterol (Serevent): DPI, every 12 hours.
Formoterol: DPI, every 12 hours.
Albuterol: Extended release oral tablets, every 12 hours.
Leukotriene Modifiers (Montelukast)
Oral medications used for long-term therapy:
Not for rescue therapy.
Inhibit synthesis or activity of leukotrienes.
Recommended for persistent asthma; preferred or alternate treatment for children under 11.
Methylxanthines
Theophylline as an oral bronchodilator:
Not the preferred asthma treatment due to narrow therapeutic index.
Requires blood level monitoring and shows moderate effectiveness.
Role of the Athletic Trainer in Asthma Management
Key responsibilities include:
Patient education on asthma and medication usage.
Monitoring compliance and overall effectiveness of medications.
Use of inhalers, spacers, and peak flow meters.
Managing asthma symptoms.
Monitoring Asthma Effectiveness
Assessing the use of rescue medication:
Excessive usage may indicate poor asthma control requiring reevaluation of long-term therapy.
A stepwise approach is essential for managing asthma effectively.
Exercise-Induced Bronchospasm Management
Recommendations:
Use quick-relief medication 5 to 15 minutes before exercise.
Additional puffs may be necessary if symptoms arise during exercise.
Frequent symptoms necessitate evaluation of long-term therapy strategies.
Educating Athletes about Peak Flow Meters
Educate on proper use for monitoring PEF:
Establish a personal best during a controlled asthma period.
Monitor for decreases indicating airflow obstruction and set management plans with a physician.
Overview of Allergies
General information on allergens and their effects on individuals.
Sensitization to an Allergen
Details on how individuals may become sensitized to allergens, referencing primary sources.
Response to an Allergen
Outline of physiological and symptomatic responses associated with allergens, citing relevant literature.
Antihistamines
Function: Block the action of histamine via different receptors:
H1: Found in respiratory tract and peripheral blood vessels.
H2: Found in the GI tract.
H3: Found in the CNS.
Types of Antihistamines
First Generation:
Diphenhydramine (Benadryl)
Chlorpheniramine (Chlor-Trimeton)
Doxylamine (Unisom)
Second Generation:
Loratadine (Claritin)
Cetirizine (Zyrtec)
Fexofenadine (Allegra)
Desloratadine (Clarinex)
Levocetirizine (Xyzal)
Antihistamines: Adverse Effects
First-generation antihistamines can cause:
Sedation, slowed reaction time, "hangover effect," and paradoxical excitation.
Anticholinergic effects including dry mouth, urinary retention, blurred vision, tachycardia, reduced sweating, and constipation.
Corticosteroids
Topical Corticosteroids:
Used in nasal sprays for allergic rhinitis.
Inhibit production of inflammatory mediators and alleviate symptoms such as runny nose, itching, and sneezing.
Oral Corticosteroids:
Indicated for use in severe allergic symptoms; potential for adverse effects exists.
Nasal Corticosteroids
Characteristics:
Slower onset of action; benefits seen in 1 to 3 days with maximal effects in 2 to 3 weeks.
Most effective when used for several weeks prior to and during exposure to allergens.
Minor adverse effects exist, and systemic effects are rare.
Mast Cell Stabilizers
Action: Decrease release of histamine in response to allergens.
Example: Cromolyn (Nasalcrom) as an OTC nasal spray, typically dosed 3 to 4 times/day.
Generally less effective than corticosteroids; may cause nasal irritation.
Ocular Inflammation Treatment for Allergies
Various systemic and ophthalmic medications are available:
Antihistamines
Corticosteroids
Decongestants
Mast cell stabilizers
NSAIDs.
Ophthalmic Products
Categories and examples:
Antihistamine: Olopatadine (Patanol, Rx)
Corticosteroid: Dexamethasone (Dexasol, Rx)
Mast cell stabilizer: Nedocromil (Alocril, Rx)
NSAID: Ketorolac (Acular, Rx)
Ophthalmic decongestant: Oxymetazoline (Visine L.R., OTC)
Role of the Athletic Trainer in Allergy Management
Responsibilities include monitoring effectiveness of treatments, educating proper medication usage, and distinguishing between allergy and cold symptoms.
Engagement in non-drug therapy and prevention strategies to support patient health.